CD274 and non-small cell lung carcinoma: The recent approval of cemiplimab in NSCLC was based on published data from the EMPOWER-Lung 1 trial, in which treatment with cemiplimab resulted in significantly longer overall survival (OS) and progression-free survival (PFS), reducing the risk of death by 43.4% in patients with PD-L1 ⩾50% and by 32.4% in the intention-to-treat (ITT) population versus chemotherapy.24